PMID- 19519256
OWN - NLM
STAT- MEDLINE
DCOM- 20090818
LR  - 20131121
IS  - 1557-8992 (Electronic)
IS  - 1044-5463 (Linking)
VI  - 19
IP  - 3
DP  - 2009 Jun
TI  - Long-term safety and efficacy of guanfacine extended release in children and 
      adolescents with attention-deficit/hyperactivity disorder.
PG  - 215-26
LID - 10.1089/cap.2008.0080 [doi]
AB  - OBJECTIVE: Short-term, controlled studies of extended-release guanfacine (GXR), a 
      selective alpha(2A)-adrenoreceptor agonist, demonstrate efficacy in treating 
      attention-deficit/hyperactivity disorder (ADHD) symptoms as monotherapy. This 
      2-year open-label study was conducted to further assess the long-term safety and 
      efficacy of GXR. METHODS: Study participants, aged 6-17 years with ADHD, had 
      previously been exposed to GXR therapy alone or in combination with 
      psychostimulants in one of two antecedent trials. In this study, doses were 
      titrated to 1, 2, 3, or 4 mg/day of GXR alone or in combination with a 
      psychostimulant. Safety and efficacy data collected at clinic visits over 24 
      months provided further evidence of the overall safety and efficacy of GXR for 
      treating ADHD. RESULTS: The majority of adverse events (AEs) were mild to 
      moderate, and few patients discontinued the study because of an AE. Efficacy 
      measures demonstrated significant improvement beginning in the first month and 
      lasting through the end of the 24-month treatment period. Throughout the entire 
      2-year study, 202 subjects (77.1%) discontinued and 60 (22.9%) completed the 
      study. CONCLUSIONS: Overall, these data support that GXR monotherapy is generally 
      safe and effective for treating ADHD.
FAU - Sallee, Floyd R
AU  - Sallee FR
AD  - Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio 45219, USA. 
      floyd.sallee@uc.edu
FAU - Lyne, Andrew
AU  - Lyne A
FAU - Wigal, Timothy
AU  - Wigal T
FAU - McGough, James J
AU  - McGough JJ
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Adrenergic alpha-Agonists)
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Delayed-Action Preparations)
RN  - 30OMY4G3MK (Guanfacine)
SB  - IM
MH  - Adolescent
MH  - Adrenergic alpha-Agonists/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Attention Deficit Disorder with Hyperactivity/*drug therapy
MH  - Central Nervous System Stimulants/therapeutic use
MH  - Child
MH  - Delayed-Action Preparations
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Guanfacine/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Treatment Outcome
EDAT- 2009/06/13 09:00
MHDA- 2009/08/19 09:00
CRDT- 2009/06/13 09:00
PHST- 2009/06/13 09:00 [entrez]
PHST- 2009/06/13 09:00 [pubmed]
PHST- 2009/08/19 09:00 [medline]
AID - 10.1089/cap.2008.0080 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2009 Jun;19(3):215-26. doi: 
      10.1089/cap.2008.0080.